← Leaderboards
Franco M Muggia
New York University School Of Medicine
$5,360,861
Attributed
$5,360,861
Total exposure
40
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $686.7K · FY2005–12$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$4,824,117 · 39
FDA$536,744 · 1
By mechanism
T32$2,341,910 · 1
U01$992,168 · 1
M01$877,098 · 33
R01$536,744 · 1
K12$509,220 · 1
P30$86,221 · 1
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Dan Vlad Iosifescu$5,888,556
- Howard S Hochster$9,390,994
- John Curtin$59,043
- Sally E Blank$145,946
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHuman Therapy EvaluationNeoplasm /Cancer ChemotherapyCombination ChemotherapyCis Platinum CompoundDrug Screening /EvaluationClinical Trial Phase IPaclitaxelAntineoplasticsFemaleDoxorubicinDrug Adverse EffectClinical TrialsNeoplasm /CancerMalignant NeoplasmsCombination Cancer TherapyPeritoneal CavityDosageCarboplatinResearch PersonnelFundingGrantLiposomes
Grant awards (107)
Protocol Specific Research Support$24,741
P30 · FY2012 · CA · contact PI
Protocol Specific Research Support$16,325
P30 · FY2011 · CA · contact PI
Symposium on Hereditary Breast and Ovarian Cancers: Lessening the Burde$5,000
R13 · FY2011 · CA · contact PI
Protocol Specific Research Support$17,185
P30 · FY2010 · CA · contact PI
Research Training in Cancer Medicine$250,329
T32 · FY2009 · CA · contact PI
Protocol Specific Research Support$17,832
P30 · FY2009 · CA · contact PI
Symposium on Hereditary Breast & Ovarian Cancers: Risk and Challenges$12,500
R13 · FY2009 · CA · contact PI
Research Training in Cancer Medicine$251,666
T32 · FY2008 · CA · contact PI
CANCER SCREENING AND PREVENTION PROJECT FOR HIGH RISK WOMEN$16,654
M01 · FY2008 · RR · contact PI
Protocol Specific Research Support$10,138
P30 · FY2008 · CA · contact PI
CLINICAL TRIAL: PACLITAXEL WITH GLEEVEC IN TAXANE-PRETREATED OVARIAN CANCER$677
M01 · FY2008 · RR · contact PI
Research Training in Cancer Medicine$253,502
T32 · FY2007 · CA · contact PI
PHASE II STUDY OF INTRAPERITONEAL FLOXURIDINE IN GASTRI*$186,595
R01 · FY2007 · FD · contact PI
CANCER SCREENING AND PREVENTION PROJECT FOR HIGH RISK WOMEN$39,057
M01 · FY2007 · RR · contact PI
IP THERAPY WITH CISPLATIN OR CARBOPLATIN AND FLOXURIDINE FOR OVARIAN & GI CANCER$5,128
M01 · FY2007 · RR · contact PI
PHASE I ORAL CAPECITABINE + CISPLATIN FOR ADVANCED DIGESTIVE SYSTEM CANCERS$3,157
M01 · FY2007 · RR · contact PI
PHASE II STUDY OF INTRAPERITONEAL FLOXURIDINE IN GASTRI*$350,149
R01 · FY2006 · FD · contact PI
Research Training in Cancer Medicine$221,991
T32 · FY2006 · CA · contact PI
INTERPERITONEAL FUDR PLUS RADIATION IN LOCALLY ADVANCED GASTRIC ADENOCARCINOMA$43,021
M01 · FY2006 · RR · contact PI
PHASE I ORAL CAPECITABINE + CISPLATIN FOR ADVANCED DIGESTIVE SYSTEM CANCERS$36,474
M01 · FY2006 · RR · contact PI
CANCER SCREENING AND PREVENTION PROJECT FOR HIGH RISK WOMEN$32,266
M01 · FY2006 · RR · contact PI
VACCINATION WITH CONJUGATED FOLLICULAR LYMPHOMA-DERIVED IDIOTYPE PLUS GM-CSF$2,806
M01 · FY2006 · RR · contact PI
Research Training in Cancer Medicine$234,063
T32 · FY2005 · CA
INTERPERITONEAL FUDR PLUS RADIATION IN LOCALLY ADVANCED GASTRIC ADENOCARCINOMA$142,759
M01 · FY2005 · RR
PHASE I ORAL CAPECITABINE + CISPLATIN FOR ADVANCED DIGESTIVE SYSTEM CANCERS$64,456
M01 · FY2005 · RR
CANCER SCREENING AND PREVENTION PROJECT FOR HIGH RISK WOMEN$36,764
M01 · FY2005 · RR
ORAL VINORELBINE WITH CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS$16,233
M01 · FY2005 · RR
A PHASE II STUDY OF DOXIL AND DOCETAXEL AS THERAPY OF ENDOMETRIAL CANCER$8,594
M01 · FY2005 · RR
TOPOTECAN &CISPLATIN INTRAPERITONEAL THERAPY FOR SOLID PERITONEAL TUMORS$6,685
M01 · FY2005 · RR
VACCINATION WITH CONJUGATED FOLLICULAR LYMPHOMA-DERIVED IDIOTYPE PLUS GM-CSF$2,388
M01 · FY2005 · RR
RESEARCH TRAINING IN CANCER MEDICINE$240,797
T32 · FY2004 · CA
Topotecan &Cisplatin Intraperitoneal Therapy for Solid Peritoneal Tumors$52,805
M01 · FY2004 · RR
Cancer Screening and Prevention Project for High Risk Women$34,806
M01 · FY2004 · RR
Epothiolone B Analog in Patients with Solid Tumors &Gynecological Malignancies$20,832
M01 · FY2004 · RR
A Phase II Study of Doxil and Docetaxel as Therapy of Endometrial Cancer$19,563
M01 · FY2004 · RR
Phase I Oral Capecitabine + Cisplatin for Advanced Digestive System Cancers$16,781
M01 · FY2004 · RR
Interperitoneal FUDR plus Radiation in Locally Advanced Gastric Adenocarcinoma$15,752
M01 · FY2004 · RR
Oral Vinorelbine with Carboplatin in Patients with Advanced Solid Tumors$4,319
M01 · FY2004 · RR
Vaccination with Conjugated Follicular Lymphoma-Derived Idiotype plus GM-CSF$2,795
M01 · FY2004 · RR
IP Therapy w/ Cisplatin or Carboplatin &FUdR for Ovarian &GI Cancer$254
M01 · FY2004 · RR
RESEARCH TRAINING IN CANCER MEDICINE$230,628
T32 · FY2003 · CA
PHASE I STUDIES OF ANTICANCER DRUG AND GENE THERAPY$402,259
U01 · FY2002 · CA
RESEARCH TRAINING IN CANCER MEDICINE$234,915
T32 · FY2002 · CA
TAXOL AND ESTRAMUSTINE IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA$0
M01 · FY2002 · RR
DOXIL AND CISPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS$0
M01 · FY2002 · RR
SAFETY/EFFICACY OF TAXOL/ESTRAMUSTINE IN HORMONE REFRACTORY PROSTATE CANCER$0
M01 · FY2002 · RR
DOXIL AND STRONTIUM IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER$0
M01 · FY2002 · RR
INTERPERITONEAL THERAPY WITH CISPLATIN/CARBOPLATIN AND FUDR IN OVARIAN CANCER$0
M01 · FY2002 · RR
SINGLE SQ DOSE OF PROCRIT FOR TREATMENT OF ANEMIA DUE TO PLATINUM REGIMENS$0
M01 · FY2002 · RR
PROCRIT VS PLACEBO IN ANEMIC BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY$0
M01 · FY2002 · RR
AMIFOSTINE AS CYTOPROTECTOR OF GEMCITABINE &CISPLATIN COMBINATION$0
M01 · FY2002 · RR
CORRELATION BETWEEN COMPLEMENT ACTIVATION &HYPERSENSITIVITY TO CHEMOTHERAPY$0
M01 · FY2002 · RR
CISPLATIN &CARBOPLATIN INDUCED DNA PROTEIN CROSS LINKS IN CANCER PATIENTS$0
M01 · FY2002 · RR
TOPOTECAN &CISPLATIN INTRAPERITONEAL THERAPY FOR SOLID PERITONEAL TUMORS$0
M01 · FY2002 · RR
INTRAPERITONEAL ADMINISTRATION OF 9 AC FOR PERITONEAL CAVITY CANCERS$0
M01 · FY2002 · RR
PHASE I STUDIES OF ANTICANCER DRUG AND GENE THERAPY$393,644
U01 · FY2001 · CA
ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$254,610
K12 · FY2001 · CA
RESEARCH TRAINING IN CANCER MEDICINE$218,628
T32 · FY2001 · CA
TOPOTECAN &CISPLATIN INTRAPERITONEAL THERAPY FOR SOLID PERITONEAL TUMORS$0
M01 · FY2001 · RR
SINGLE SQ DOSE OF PROCRIT FOR TREATMENT OF ANEMIA DUE TO PLATINUM REGIMENS$0
M01 · FY2001 · RR
INTERPERITONEAL THERAPY WITH CISPLATIN/CARBOPLATIN AND FUDR IN OVARIAN CANCER$0
M01 · FY2001 · RR
DOXIL AND STRONTIUM IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER$0
M01 · FY2001 · RR
SAFETY/EFFICACY OF TAXOL/ESTRAMUSTINE IN HORMONE REFRACTORY PROSTATE CANCER$0
M01 · FY2001 · RR
TAXOL AND ESTRAMUSTINE IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA$0
M01 · FY2001 · RR
DOXIL AND CISPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS$0
M01 · FY2001 · RR
INTRAPERITONEAL ADMINISTRATION OF 9 AC FOR PERITONEAL CAVITY CANCERS$0
M01 · FY2001 · RR
PROCRIT VS PLACEBO IN ANEMIC BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY$0
M01 · FY2001 · RR
AMIFOSTINE AS CYTOPROTECTOR OF GEMCITABINE &CISPLATIN COMBINATION$0
M01 · FY2001 · RR
CORRELATION BETWEEN COMPLEMENT ACTIVATION &HYPERSENSITIVITY TO CHEMOTHERAPY$0
M01 · FY2001 · RR
CISPLATIN &CARBOPLATIN INDUCED DNA PROTEIN CROSS LINKS IN CANCER PATIENTS$0
M01 · FY2001 · RR
ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$254,610
K12 · FY2000 · CA
RESEARCH TRAINING IN CANCER MEDICINE$205,391
T32 · FY2000 · CA
PHASE I STUDIES OF ANTICANCER DRUG AND GENE THERAPY$196,265
U01 · FY2000 · CA
INTRAPERITONEAL ADMINISTRATION OF 9 AC FOR PERITONEAL CAVITY CANCERS$21,006
M01 · FY2000 · RR
CISPLATIN &CARBOPLATIN INDUCED DNA PROTEIN CROSS LINKS IN CANCER PATIENTS$21,006
M01 · FY2000 · RR
CORRELATION BETWEEN COMPLEMENT ACTIVATION &HYPERSENSITIVITY TO CHEMOTHERAPY$21,006
M01 · FY2000 · RR
TAXOL AND ESTRAMUSTINE IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA$21,006
M01 · FY2000 · RR
DOXIL AND STRONTIUM IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER$21,006
M01 · FY2000 · RR
AMIFOSTINE AS CYTOPROTECTOR OF GEMCITABINE &CISPLATIN COMBINATION$21,006
M01 · FY2000 · RR
PROCRIT VS PLACEBO IN ANEMIC BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY$21,006
M01 · FY2000 · RR
DOXIL AND CISPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS$21,006
M01 · FY2000 · RR
SINGLE SQ DOSE OF PROCRIT FOR TREATMENT OF ANEMIA DUE TO PLATINUM REGIMENS$21,006
M01 · FY2000 · RR
SAFETY/EFFICACY OF TAXOL/ESTRAMUSTINE IN HORMONE REFRACTORY PROSTATE CANCER$21,006
M01 · FY2000 · RR
INTERPERITONEAL THERAPY WITH CISPLATIN/CARBOPLATIN AND FUDR IN OVARIAN CANCER$21,006
M01 · FY2000 · RR
TOPOTECAN &CISPLATIN INTRAPERITONEAL THERAPY FOR SOLID PERITONEAL TUMORS$21,006
M01 · FY2000 · RR
CISPLATIN &CARBOPLATIN INDUCED DNA PROTEIN CROSS LINKS IN CANCER PATIENTS$0
M01 · FY2000 · RR
DOXIL AND STRONTIUM IN HORMONE REFRACTORY METASTATIC PROSTATE CANCER$0
M01 · FY2000 · RR
SAFETY/EFFICACY OF TAXOL/ESTRAMUSTINE IN HORMONE REFRACTORY PROSTATE CANCER$0
M01 · FY2000 · RR
TAXOL AND ESTRAMUSTINE IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA$0
M01 · FY2000 · RR
DOXIL AND CISPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS$0
M01 · FY2000 · RR
PHASE I STUDY OF PS 341 IN ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR
PHASE I STUDY OF PS 341 IN ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR
DOXIL AND PACLITAXEL IN ENDOMETRIAL, TUBAL SARCOMA$0
M01 · FY2000 · RR
DOXIL AND PACLITAXEL IN ENDOMETRIAL, TUBAL SARCOMA$0
M01 · FY2000 · RR
BMS 217380 01, DOXORUBICIN AND TAXOL FOR BREAST CANCER$0
M01 · FY2000 · RR
BMS 217380 01, DOXORUBICIN AND TAXOL FOR BREAST CANCER$0
M01 · FY2000 · RR
PACLITAXEL, ESTRAMUSTINE PHOSPHATE AND VINORELBINE$0
M01 · FY2000 · RR
PACLITAXEL, ESTRAMUSTINE PHOSPHATE AND VINORELBINE$0
M01 · FY2000 · RR
GEMCITABINE, CISPLATIN ,AMIFOSTINE IN OVARIAN CANCER$0
M01 · FY2000 · RR
GEMCITABINE, CISPLATIN ,AMIFOSTINE IN OVARIAN CANCER$0
M01 · FY2000 · RR
INTRAPERITONEAL ADMINISTRATION OF 9 AC FOR PERITONEAL CAVITY CANCERS$0
M01 · FY2000 · RR
TOPOTECAN &CISPLATIN INTRAPERITONEAL THERAPY FOR SOLID PERITONEAL TUMORS$0
M01 · FY2000 · RR
INTERPERITONEAL THERAPY WITH CISPLATIN/CARBOPLATIN AND FUDR IN OVARIAN CANCER$0
M01 · FY2000 · RR
CORRELATION BETWEEN COMPLEMENT ACTIVATION &HYPERSENSITIVITY TO CHEMOTHERAPY$0
M01 · FY2000 · RR
AMIFOSTINE AS CYTOPROTECTOR OF GEMCITABINE &CISPLATIN COMBINATION$0
M01 · FY2000 · RR
PROCRIT VS PLACEBO IN ANEMIC BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY$0
M01 · FY2000 · RR
SINGLE SQ DOSE OF PROCRIT FOR TREATMENT OF ANEMIA DUE TO PLATINUM REGIMENS$0
M01 · FY2000 · RR